ElevateBio is a biotechnology startup that operates in the cell and gene therapy market. The company combines manufacturing, next-generation technologies, and therapeutic development to create a comprehensive solution for cell and gene therapies. Their business model involves the use of their proprietary technologies, such as gene editing and induced pluripotent stem cell (iPSC), to develop and manufacture these therapies.

The company serves a range of clients, including other biotech companies and healthcare providers. They have partnerships with companies like Kyverna Therapeutics and Novo Nordisk to advance cell therapy manufacturing and develop gene editing therapies for rare and cardiometabolic diseases, respectively.

ElevateBio's revenue comes from the commercialization of their therapies and the services they provide to their partners. They also make money from their presentations at industry events, such as the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, where they highlight their processes for viral vector production.

The company's unique selling point is their integrated ecosystem of technologies and capabilities, which allows them to discover, develop, manufacture, and commercialize a broad spectrum of cell and gene therapies and regenerative medicines. This approach enables them to focus on differentiated technologies and R&D efforts, while simultaneously removing barriers to knowledge and new scientific breakthroughs.

Keywords: Biotechnology, Cell Therapy, Gene Therapy, Manufacturing, Next-Generation Technologies, Therapeutic Development, Gene Editing, Induced Pluripotent Stem Cell (iPSC), Partnerships, Commercialization.